iwCLL 2023 | The role of allo transplantation in CLL
Paula Cramer, MD, University of Cologne, Cologne, Germany, discusses allogeneic (allo) stem cell transplantation, a treatment which no longer plays a major role in treatment of chronic lymphocytic leukemia (CLL) due to the development of novel therapies, which are more appropriate for the majority of patients. Patients with CLL who have already received novel agents but had to terminate treatment due to intolerance or progression will ideally be enrolled into a clinical trial, however if this is not possible, the patient is young, and a donor is found, allo transplantation may be considered. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
